Table 3 Indications for controls

Controls over time:

No agreed indication

Monitoring TSH and fT4 at least every 3 months in patients on one phosphate binder + one other potentially interfering drug (on the basis of the high levels found in the previous studies, and in ours)

Monthly monitoring if unstable TSH or if new potentially interfering drugs, change in dose of phosphate binder, or more than 2 potentially interfering drugs (importance of early diagnosis)

Reduce frequency when there has been long-term stability, and no change in treatment (probably wise to monitor patient at least twice a year)